Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry

Inclusion Criteria: * Histological diagnosis of lung cancer, either NSCLC or SCLC patients and carcinoid tumours * Untreated lung cancer of any stage and any treatment (including palliative care only). * Availability for participating in the detailed follow-up of the protocol. * Signed informed consent. * Age above 18 years. * Presence of at least one co-morbidity: * Any active or past cardiac ischemia * Reduced left ventricular ejection fraction (\< 50%) * Obstructive cardiomyopathy * Valvular dysfunction (3 or 4/4; valvular replacement) * Arrhythmia (atrial flutter or fibrillation, significant ventricular arrhythmia, 2nd-3rd degree auriculo-ventricular block, Wolf-Parkinson-White and other similar aberrant conduction, bifascicular block, arrhythmogenic right ventricular dysplasia) * Uncontrolled hypertension (systolic blood pressure (BP) \> 160 millimeter of mercury (mmHg) or diastolic BP \> 100 mmHg on ≥ 1 hypotensive drug) or controlled hypertension on ≥ 2 concurrent hypotensive drugs * Active or treated peripheral arteritis (grade 2 or more) * Cerebrovascular events * Pulmonary embolism and/or thrombophlebitis or patients at high risk of thrombophilia (homozygous Leiden factor…) * Aortic aneurism Exclusion Criteria: * Thymoma and thymic malignancies, pleural mesothelioma. * Patient previously treated for lung cancer. * Tumours for which complete staging cannot be assessed. * History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval).